3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Conditions
Melanoma
2
Sezary Syndrome
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Hepatitis
1
Colitis
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
137
Nivolumab
116
Ipilimumab
68
Cyclophosphamide
33
Specimen Handling
31
Magnetic Resonance Spectroscopy
28
trametinib
23
binimetinib
22
fludarabine
21
Interleukin-2
20
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
CTLA-4 Antigen
16
cemiplimab
15
atezolizumab
15
aldesleukin
15
Radiosurgery
15
fludarabine phosphate
14
Opdualag
14
Radiotherapy
11
lenvatinib
10
Blood Specimen Collection
10
lifileucel
9
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
spartalizumab
7
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
Methoxsalen
×
1 year
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled
NCT06646016
2025-12-26
EPIC
Therakos LLC
Phase 2
Withdrawn